In Depth 30 Jul 2024
Why is the immunology and inflammation market suddenly attracting a wave of investment?
Discover why the immunology and inflammation market has recently been attracting a major wave of investment.
- Latest Posts
News and Trends 29 Jul 2024
Influenza solution deals pile up as pandemic preparedness increases
Influenza deals have been piling up in the last few weeks. Discover why that is and how are companies and government preparing for pandemics.
Podcast 26 Jul 2024
The first mass-market cell therapy?
Listen to our conversation with CEO Greg Kunst about how Aurion’s treatment could be the first mass-market cell therapy available
More News! 26 Jul 2024
Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies
Discover the field of agonistic GPCR antibodies after Confo therapeutics successfully raised $60 million in its series B round.
In Depth 25 Jul 2024
The future of inflammatory bowel disease treatment: what is on the horizon?
Ongoing clinical trials aim to address inflammatory bowel disease, which is caused by an overactive immune system that causes symptoms affecting the gut.
In Depth 24 Jul 2024
Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?
Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market.
ADVERTISEMENT
ADVERTISEMENT
More News! 23 Jul 2024
First AKT-targeting drug capivasertib to hit the market, could it open the door for more?
As AstraZeneca and Astex’s capivasertib gains market presence in breast cancer, could it be the time for AKT inhibitors? Let’s find out!
Expert Advice 19 Jul 2024
The ABC of biotech partnerships
Discover eight different types of biotech partnerships, including what each one entails and its advantages and disadvantages.
Podcast 19 Jul 2024
Cutting through the AI hype in drug discovery
There’s certainly hype around AI, but what can it really do in drug discovery? Listen to our conversation with LabGenius to find out.
In Depth 18 Jul 2024
Lenacapavir: Can Gilead’s drug end the HIV pandemic?
Discover more about Gilead’s lenacapavir, which recently demonstrated 100% efficacy for HIV prevention in a phase 3 trial.
More News! 17 Jul 2024
Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it
Discover yet another exciting deal in biotech with Asceneuron raising $100 million to advance its Alzheimer’s candidate, ASN51.
How a microbial expression update is driving biotech innovation
Discover how microbial expression systems are revolutionizing protein production for next-gen therapies like antibodies and peptides.
ADVERTISEMENT
